• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • T Regulatory Cell Therapies
      • SOD1 Therapies & Trials
    • Approved Drugs
      • Neudexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day
    • March of Faces
    • Patient Fellows Program
    • International Symposium
  • About
    • Who We Are
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Student Innovation Award
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
  • Members
    • Member Registration
    • Forgot Password

Patient Networks, Online Support Groups, Blogs

Professor Stephen Hawking

February 27, 2018 by

In 1963, Hawking contracted motor neurone disease and was given two years to live. Yet he went on to Cambridge to become a brilliant researcher and Professorial Fellow at Gonville and Caius College. From 1979 to 2009 he held the post of Lucasian Professor at Cambridge, the chair held by Isaac Newton in 1663. Professor Hawking has over a dozen honorary degrees and was awarded the CBE in 1982. He is a fellow of the Royal Society and a member of the US National Academy of Science. Stephen Hawking is regarded as one of the most brilliant theoretical physicists since Einstein.

Alper Kaya: Living with ALS/MND in Turkey

February 27, 2018 by

Paralleltreffen für Betroffene und Angehörige (Switzerland)

February 27, 2018 by

Unser Hauptanliegen als ALS-Patientenorganisation ist seit jeher die bestmögliche Begleitung und Unterstützung Direktbetroffener und ihrer Angehörigen.

Mit den Paralleltreffen möchten wir Raum öffnen, sich mit anderen zu vernetzen, voneinander zu lernen. Und dabei für einmal als Direktbetroffener oder Angehörige die eigenen Bedürfnisse ins Zentrum setzen zu dürfen. Anstelle der sonst zuvorderst stehenden Rücksichtnahme auf den Partner oder die Partnerin im gemeinsamen Leben mit ALS.

Die Teilnahme ist kostenlos und steht allen interessierten Personen offen. Beliebig oft und an beliebig vielen Orten.

ALS Forum

February 27, 2018 by

Welcome to the ALS Forum. We were started in 2000 by the ALS Therapy Development Foundation (now Institute), which continues to moderate with the help of long-time forum members. The purpose of this forum is to exchange information about ALS, scientific advances in ALS, and treatments for ALS. Forum members include people living with ALS today as well as their care providers, family members, friends, neurologists as well as neurodegenerative disease researchers and pharmaceutical executives. We encourage an open dialogue and the sharing of ideas and opinions. However, bad language, disparaging remarks, personal attacks, marketing, or inappropriate remarks will be removed and may lead to termination of forum privileges. If you have any questions about the use of this forum, or experience difficulties, please email us at info@als.net.

La ELA y Enrry Blog

February 27, 2018 by

La creación de este blog, es para reseñar mi historia de esta enfermedad (Esclerosis Lateral Amiótrofica) y dar información de la misma y para tratar de ayudar por mis experiencias vividas, a otras personas y que aparezca en el blog y los enlace de ayuda, para el que padece la enfermedad o el familiar o al público en general, revisen y se orienten. ¿POR QUE HOY ME TOCO A MI Y MAÑANA PUEDE SER TU O UN FAMILIAR? LA ELA FORMA PARTE DE LA VIDA Y LA ELA EXISTE.

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

Back to resources

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login